The FDA has approved Eli Lilly’s new rapid-acting insulin Lyumjev (insulin lispro-aabc injection) for increasing glycemic control in adults with type 1 and type 2 diabetes.

The approval was based on two phase 3 clinical trials in which Lyumjev demonstrated superior reduction in blood glucose spikes compared to Humalog at one hour and two hours after a meal.

Lyumjev is a novel formulation of insulin lispro developed to speed absorption of insulin into the bloodstream and reduce average blood sugar levels.